Abstract Library

#4100 Pheochromocytoma and paraganglioma: Gender differences in lipid profile

Introduction: Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine neoplasms potentially influencing lipid metabolism and increasing cardiovascular risk. Gender differences in PPGL are largely unknown.

Conference:

Presenting Author: Di Iasi G

Authors: Di Iasi G, Benevento E, Cannavale G, Liccardi A, Minotta R,

Keywords: gender, Pheochromocytoma, paraganglioma, lipid, cholesterol,

#3782 Somatostatin analogues (SSA) in gastroenteropancreatic neuroendocrine tumors (GEP-NET) – Impact on glycemia and lipid profile in a monocentric series

Introduction: Somatostatin analogues (SSA) are often the first line therapy in neuroendocrine tumors (NET). The management of hyperglycaemia and dyslipidaemia are one of the most important challenges in healthcare. The impact of SSA on metabolic profile in GEP-NET is highly debated.

Conference:

Presenting Author: Cannavale G

Authors: Cannavale G, Benevento E, Minotta R, Liccardi A, Modica R,

Keywords: SSA, lipid profile, glycemia, GEP-NET, hyperglycaemia, Somatostatin analogues,

#2819 Occurrence of Pancreatic Exocrine Insufficiency in Patients with Advanced Neuroendocrine Tumours Treated with Somatostatin Analogue

Introduction: Neuroendocrine neoplasia (NENs) are heterogeneous tumours caracterized by a relatively indolent rate of growth. Usually, in G1 and G2 GEP-NENs, first-line therapy is SSAs, considering their efficacy, good safety profile, and antiproliferative effects. SSA treatment inhibits the production and excretion of pancreatic enzymes and PEI is known to be an adverse effect of SSA treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rinzivillo M

Authors: De Felice I, Rinzivillo M, Pratesi M, Magi L, Annibale B,

Keywords: Pancreatic Exocrine Insufficiency,

#2770 Evaluation of Early Predictors of Metabolic Syndrome in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

Introduction: Metabolic syndrome and obesity (MetS) are supposed to have a role in cancer but data analysing their association with GEP-NET are lacking.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Modica R

Authors: Modica R, Barrea L, Bottiglieri F, de Cicco F, Minotta R,

Keywords: GEP-NET, metabolic syndrome, visceral adiposity index, fatty liver index,

#2112 Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F,

Keywords: adverse events, everolimus, RADIANT-3, RADIANT-4, landmark analysis, mTOR inhibitors, targeted therapy, neuroendocrine tumors,